Heska (HSKA) Stock Rating Lowered by BidaskClub

BidaskClub downgraded shares of Heska (NASDAQ:HSKA) from a buy rating to a hold rating in a research note published on Thursday morning.

Other analysts have also recently issued reports about the company. Benchmark initiated coverage on Heska in a research report on Thursday, July 19th. They issued a buy rating and a $120.00 price objective for the company. TheStreet cut Heska from a b rating to a c+ rating in a research report on Monday, August 20th. ValuEngine cut Heska from a buy rating to a hold rating in a research report on Monday, July 30th. Finally, Zacks Investment Research upgraded Heska from a strong sell rating to a hold rating in a research report on Wednesday, July 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $107.50.

Shares of Heska stock traded up $0.67 on Thursday, reaching $102.99. The company’s stock had a trading volume of 56,812 shares, compared to its average volume of 67,230. The stock has a market capitalization of $756.30 million, a PE ratio of 49.75 and a beta of 0.73. Heska has a 52-week low of $56.59 and a 52-week high of $114.50.

Heska (NASDAQ:HSKA) last posted its quarterly earnings data on Tuesday, November 6th. The medical research company reported $0.46 EPS for the quarter, beating the Zacks’ consensus estimate of $0.35 by $0.11. The business had revenue of $30.96 million during the quarter, compared to analysts’ expectations of $31.14 million. Heska had a return on equity of 11.48% and a net margin of 1.01%. Equities analysts forecast that Heska will post 1.67 EPS for the current fiscal year.

In related news, EVP Steven M. Eyl sold 33,351 shares of the business’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $98.49, for a total transaction of $3,284,739.99. Following the completion of the sale, the executive vice president now directly owns 15,401 shares in the company, valued at $1,516,844.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jason A. Napolitano sold 2,500 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $111.50, for a total value of $278,750.00. The disclosure for this sale can be found here. Insiders have sold 56,777 shares of company stock valued at $5,751,062 over the last quarter. 14.70% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of HSKA. Piedmont Investment Advisors LLC purchased a new stake in shares of Heska during the second quarter worth approximately $162,000. SG Americas Securities LLC purchased a new stake in shares of Heska during the second quarter worth approximately $191,000. Paloma Partners Management Co purchased a new stake in shares of Heska during the second quarter worth approximately $228,000. Macquarie Group Ltd. purchased a new stake in shares of Heska during the second quarter worth approximately $234,000. Finally, Raymond James Trust N.A. purchased a new stake in shares of Heska during the second quarter worth approximately $240,000. Hedge funds and other institutional investors own 88.63% of the company’s stock.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Recommended Story: Why is the conference call important?

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply